CDEK
← All drugs Report issue

mesna

Trade name: mesnex

Small moleculeapprovedOrphan Drug FDA

Approved

Aug 14, 1987

Mesna is an organosulfur compound used as an adjuvant in cancer chemotherapy involving cyclophosphamide and ifosfamide. No clinical drug interaction studies have been conducted with mesna. Mesna concentrates in the bladder where acrolein accumulates after administration of chemotherapy and through a Michael addition, forms a conjugate with acrolein and other urotoxic metabolites. This conjugation reaction inactivates the urotoxic compounds to harmless metabolites. The most common adverse reactions (> 10%) when MESNEX is given with ifosfamide are nausea, vomiting, constipation, leukopenia, fatigue, fever, anorexia, thrombocytopenia, anemia, granulocytopenia, diarrhea, asthenia, abdominal pain, headache, alopecia, and somnolence. — NCATS

Clinical trial activity

212 trials · 149 clinical orgs · 15 marketing orgs

Phase 1
75
Phase 2
148
Phase 3
21
Phase 4
3

Earliest trial started Jul 1, 1990 (NCT00002802)

Timeline

1980s

  1. Nov 14, 1985

    Orphan Drug Designation

  2. Aug 14, 1987

    Earliest FDA Approval

  3. Aug 14, 1987

    Baxalta — NDA Secondary Org

  4. Jan 1, 1988

    Baxter — First NDA Organization

  5. Jan 1, 1988

    Baxter — NDA Organization

1990s

  1. Jan 1, 1990

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 1991

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 1992

    Earliest Phase 2 Sponsor(trial)

2000s

  1. Apr 26, 2001

    Fresenius — Marketing Organization

  2. Apr 27, 2001

    Teva — Marketing Organization

  3. Jan 9, 2004

    West-Ward Pharmaceutical — Marketing Organization

  4. Jan 9, 2004

    Hikma — Marketing Organization

2010s

  1. Apr 13, 2010

    Sagent Pharmaceuticals, Inc. — Marketing Organization

  2. Mar 8, 2012

    Mylan — Marketing Organization

  3. Jul 18, 2014

    Rising Pharmaceuticals — Marketing Organization

  4. Dec 18, 2017

    Gland Pharma Ltd — Marketing Organization

  5. Dec 18, 2017

    Fosun — Marketing Organization

2020s

  1. Jan 13, 2025

    RiconPharma — Marketing Organization

  2. Jan 13, 2025

    Novast Labs — Marketing Organization

  3. Jan 13, 2025

    Ingenus Pharmaceuticals — Marketing Organization

  4. Jan 27, 2026

    Eugia Pharma — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

  • Unspecified targetOTHER

    Unknown

Combination products

  • ifex/mesnex

    with ifosfamide

    Also known as ifosfamide/mesna

Approval history

  • approvedPriority reviewAug 14, 1987

Chemistry & pharmacology

Loading structure…

SMILES

O=S(=O)(O)CCS
Mol. weight
142.2 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral, Parenteral
Availability
Prescription Only

Oral

Yes

Parenteral

Yes

Topical

No

Sources

Also known as

  • 2-mercaptoethanesulfonate
  • 2-mercaptoethanesulfonate
  • 2-mercaptoethane sulfonate
  • 2-mercaptoethane sulfonate
  • 2-mercaptoethanesulfonic acid
  • 2-mercaptoethanesulfonic acid
  • 2-mercaptoethanesulphonic acid
  • 2-mercaptoethanesulphonic acid
  • 2-mercaptoethylsulfonate
  • 2-mercaptoethylsulfonate
  • 2-sulfanylethylsulfonate
  • 2-sulfanylethylsulfonate
  • coenzima m
  • coenzima m
  • coenzyme m
  • coenzyme m
  • coenzym m
  • coenzym m
  • com
  • com
  • d-7093
  • d-7093
  • hs-com
  • hs-com
  • mercaptoethane sulfonate
  • mercaptoethanesulfonic acid
  • mesna
  • mesna
  • mesna
  • mesna
  • mesna
  • mesna
  • mesna
  • mesna
  • mesna
  • mesna
  • mesna
  • mesnex
  • mesnex
  • mesnex
  • mistabron
  • mistabron
  • reduced coenzyme m
  • reduced coenzyme m
  • reduced coenzyme m
  • reduced com
  • reduced com
  • sodium 2-mercaptoethane sulfonate
  • sodium 2-mercaptoethane sulfonate
  • sodium-2-mercapto ethane sulphonate
  • uromitexan
  • uromitexan
  • β-mercaptoethanesulfonic acid
  • β-mercaptoethanesulfonic acid

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07257419Phase 1Dec 31, 2025St. Jude Children's Hospital
NCT07052370Phase 1Dec 31, 2025St. Jude Children's Hospital
NCT06942039Early Phase 1 (Phase 1)Sep 30, 2025C17 Council
NCT06777979Phase 1May 31, 2025St. Jude Children's Hospital
NCT06847269Phase 2Apr 30, 2025St. Jude Children's Hospital
NCT06834282Phase 1Apr 7, 2025CERo Therapeutics Holdings, Inc.
NCT06326463Phase 1Dec 31, 2024St. Jude Children's Hospital
NCT06190249Phase 1Dec 31, 2024Case Western Reserve University, Iovance
NCT06677710Phase 1Nov 1, 2024Indapta Therapeutics, INC.
NCT06345495Phase 2Oct 1, 2024Incyte, University of Texas at Houston
NCT05813327Phase 1/Phase 2 (Phase 2)Jan 31, 2024Polaris Group, Washington University in St. Louis
NCT06001385Phase 2Nov 1, 2023Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
NCT06119685Phase 1/Phase 2 (Phase 2)Oct 25, 2023Indapta Therapeutics, INC.
NCT06078696Phase 1/Phase 2 (Phase 2)Sep 28, 2023Columbia University, ITB-Med LLC
NCT05589896Phase 1/Phase 2 (Phase 2)Mar 31, 2023Center for International Blood and Marrow Transplant Research, Ossium Health, Inc.
NCT05382338Phase 3Dec 9, 2022National Cancer Institute (NCI)
NCT05579769Phase 2Nov 4, 2022St. Jude Children's Hospital
NCT05470283Phase 1Sep 7, 2022University of Texas at Houston
NCT04897321Phase 1Apr 30, 2022St. Jude Children's Hospital
NCT05207722Phase 1/Phase 2 (Phase 2)Apr 14, 2022Celularity, Inc.
Showing 20 of 212 trials
Page 1 / 11

Organizations

Research & Development (149)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of Texas at HoustonAcademic/Hospital454541994
National Cancer Institute (NCI)Government412741992
St. Jude Children's HospitalAcademic/Hospital221841991
Northwestern UniversityAcademic/Hospital111132002
Baylor UniversityAcademic/Hospital9931999
Center for International Blood and Marrow Transplant ResearchGovernment7422016
Cornell UniversityAcademic/Hospital7721995
Harvard UniversityAcademic/Hospital6431996
Johns Hopkins UniversityAcademic/Hospital6422014
National Institutes of Health (NIH)Government5022002
NovartisFor profit5012001
University of MinnesotaAcademic/Hospital5542004
Methodist Cancer Center, Houston, TexasAcademic/Hospital4031999
Millennium PharmaceuticalsFor profit4022007
National Marrow Donor ProgramGovernment4012016
University of California, San FranciscoAcademic/Hospital4032000
University of PennsylvaniaAcademic/Hospital4231995
University of PittsburghAcademic/Hospital4232000
Children's National Medical CenterAcademic/Hospital3031996
Duke UniversityAcademic/Hospital3131996
149 organizations
Page 1 / 8

Marketing (19)

OrganizationOrg typeRelationshipDate
BaxaltaFor profitNDA2Aug 14, 1987
BaxterFor profitNDAJan 1, 1988
Eugia PharmaFor profitMKTGJan 27, 2026
FosunFor profitMKTGDec 18, 2017
FreseniusFor profitMKTGApr 26, 2001
Gland Pharma LtdFor profitMKTGDec 18, 2017
Gland Pharma LtdFor profitMKTGDec 18, 2017
HikmaFor profitSYNJan 9, 2004
HikmaFor profitMKTGJan 9, 2004
Ingenus PharmaceuticalsFor profitMKTGJan 13, 2025
MylanFor profitMKTGMar 8, 2012
MylanFor profitSYNJul 18, 2014
Novast LabsFor profitMKTGJan 13, 2025
RiconPharmaFor profitMKTGJan 13, 2025
Rising PharmaceuticalsFor profitMKTGJul 18, 2014
Sagent Pharmaceuticals, Inc.For profitMKTGApr 13, 2010
Sagent Pharmaceuticals, Inc.For profitSYNApr 13, 2010
TevaFor profitMKTGApr 27, 2001
West-Ward PharmaceuticalFor profitMKTGJan 9, 2004